Sleep Disorders Clinical Trial
Official title:
Sleep Specialty Consultation: Improving Management of Sleep Disorders
Verified date | August 2014 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
Sleep disorders are prevalent health problems that reduce quality of life, increase risks for medical disease, and enhance healthcare costs/utilization. Only a small proportion of these cases are diagnosed in primary care. Pilot data from this VA suggest that sleep disorders are not adequately managed in a primary care setting: 33% of veterans with an insomnia complaint had an undiagnosed primary sleep disorder (e.g., sleep apnea), and 50% of these patients were prescribed pharmacologic treatment for insomnia by their primary care providers.
Status | Completed |
Enrollment | 156 |
Est. completion date | December 2010 |
Est. primary completion date | July 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - veteran seen at Durham VAMC for primary care; - must have had a sleep complaint for > 1 month; - not being treated by a sleep specialist for sleep complaint; - provide informed consent; - have concurrence for enrollment from their assigned MD PCP; - score >5 on the Pittsburgh Sleep Quality Index at time of screening Exclusion Criteria: - terminal illness; - acute or highly unstable Axis I psychiatric condition; - not mentally competent; - unstable living environment; - unstable medical or psychiatric condition; - established sleep disorder or currently under the care of one or more of our VAMC's sleep disorders specialists; - previous evaluation by sleep disorders specialist; - refuse to give informed consent |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Durham VA Medical Center, Durham, NC | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Edinger JD, Ulmer CS, Grubber J, Zervakis JB, Olsen MK. Effects of a One-Time Sleep Specialty Consultation on Sleep Problem Management in Primary Care. [Abstract]. Sleep. 2011 Oct 20; 34(Suppl):A337,0984.
Olsen MK, Stechuchak KM, Edinger JD, Ulmer CS, Woolson RF. Move over LOCF: principled methods for handling missing data in sleep disorder trials. Sleep Med. 2012 Feb;13(2):123-32. doi: 10.1016/j.sleep.2011.09.007. Epub 2011 Dec 14. Review. — View Citation
Zervakis JB, Ulmer CS, Edinger JD. Can a One-Time Sleep Specialty Consultation Enhance Providers' Attention to Sleep Problems in Primary Care? [Abstract]. Sleep. 2010 Mar 1; 33(Suppl):A365,1092.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Provider Adherence to Sleep Specialist Recommendations | Provider outcomes included the provider's number of participant sleep lab referrals, referrals to other specialty clinics for evaluation/treatment participant sleep problems, and presence of newly initiated sleep-focused therapies for participants. Information about these outcomes was obtained via review of provider orders and information included in notes entered into the VA's computerized medical record system (CPRS). To quantify this outcome, the number of participants referred by providers for sleep-focused diagnostic tests and interventions was compared across arms. | 10 months after baseline | No |
Primary | Diary Sleep: Total Wake Time and Total Sleep Time | Changes in sleep from baseline to subsequent follow-up periods were evaluated using both actigraphy and electronic diaries via a personal digital assistant (PDA). Primary outcome measures derived from the PDA included total sleep time (TST), total wake time (TWT: SOL+WASO), and sleep efficiency (SE). Wrist Actigraphy. Mini-MitterĀ® Actiwatch actigraphs were used to derive the primary objective estimates of TST, TWT, and SE. Mean values of TST, TWT and SE were obtained for each participant at baseline, 5 months and 10 months post-randomization and served as the actigraphic dependent measures in study analyses. | 10 months | No |
Primary | Sleep Efficiency | Changes in sleep from baseline to subsequent follow-up periods were evaluated using both actigraphy and electronic diaries via a personal digital assistant (PDA). Primary outcome measures derived from the PDA included total sleep time (TST), total wake time (TWT: SOL+WASO), and sleep efficiency (SE). Wrist Actigraphy. Mini-MitterĀ® Actiwatch actigraphs were used to derive the primary objective estimates of TST, TWT, and SE. Mean values of TST, TWT and SE were obtained for each participant at baseline, 5 months and 10 months post-randomization and served as the actigraphic dependent measures in study analyses. | 10 Months after Baseline | No |
Primary | Sleep Quality | Changes in overall sleep quality were evaluated using the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a self-rating scale that yields a quantitative index of general sleep quality/disturbances. The PSQI is composed of 4 open-ended questions and 19 self-rated items (0-3 scale) assessing sleep quality and disturbances over a 1-month interval. The PSQI yields a global score of sleep quality ranging from 0 to 21. A score of <= 5 on the PSQI is considered normal sleep quality. | 10 Months | No |
Secondary | Sleepiness | Changes in subjectively assessed daytime sleep propensity were measured using the Epworth Sleepiness Scale (ESS), a commonly employed in both sleep research and clinical applications. The ESS items inquire about the chance of dozing off in each 8 different situations. Responses are rated on a 4 point scale reflecting the respondents perceived likelihood of falling asleep. To quanitfy this outcome, the percentage of participants achieving normal sleep (less than 10 on ESS) was compared across arms at 10 months. | 10 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02188498 -
Electrocardiography Data Analysis in Sleep Disorders
|
||
Completed |
NCT00990106 -
Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00163670 -
The Impact of Sleep Disorders on Motor Vehicle Accidents
|
N/A | |
Completed |
NCT00256685 -
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
|
Phase 3 | |
Completed |
NCT00203827 -
Pediatric Sleep Questionnaire: Use for Collection of Clinical Data
|
N/A | |
Completed |
NCT00174174 -
Provigil (Modafinil) Study by Taiwan Biotech Co.
|
N/A | |
Terminated |
NCT00750919 -
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
|
Phase 3 | |
Completed |
NCT02939586 -
The Effect of Haemodialysis in Sleep Apnoea
|
N/A | |
Completed |
NCT03075241 -
Z-Drugs for Sleep Disorders in Alzheimer's Disease
|
Phase 3 | |
Completed |
NCT03055156 -
Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms
|
N/A | |
Completed |
NCT02585609 -
Sleep Quality in Patients With Advanced Cancer
|
N/A | |
Completed |
NCT01929447 -
Evaluation of WP200 With the Unified Probe (WP200U)
|
N/A | |
Completed |
NCT02156128 -
Subjective Memory Complaints, Objective Memory Performance and Cognitive Training
|
N/A | |
Completed |
NCT01906866 -
Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
|
Phase 3 | |
Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|
||
Completed |
NCT01220401 -
Efficacy of a Brief Nightmare Treatment for Veterans
|
N/A | |
Completed |
NCT01256983 -
Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
|
Phase 0 | |
Not yet recruiting |
NCT00749814 -
Sleep Disturbances in Hospitalized Children
|
Phase 4 | |
Completed |
NCT00518986 -
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
|
Phase 4 |